Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

21. Januar 2022 08:00 ET | Quelle: Arch Oncology

Arch Oncology Receives U.S. FDA Orphan Drug Designation for AO-176, a Next-Generation Anti-CD47 IgG2 Antibody, for the Treatment of Multiple Myeloma

BRISBANE, Calif. and ST. LOUIS, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 biologic...
02. August 2021 08:00 ET | Quelle: Arch Oncology

Arch Oncology Strengthens Medical and Clinical Leadership Teams with Key Appointments

– Seasoned oncology leaders Louie Naumovski, M.D., Ph.D., appointed as Chief Medical Officer; Amit Agarwal, M.D., Ph.D. as Senior V.P., Clinical Development and Steve DeMattos as Senior V.P., Clinical...
27. April 2021 07:00 ET | Quelle: Arch Oncology

Arch Oncology Secures $105 Million Series C Financing

– Proceeds to support clinical progress of differentiated anti-CD47 candidate AO-176 for patients with solid tumors and hematologic malignancies – – Series C co-led by new investors Eventide Asset...